A sturdy house at an ordinary price: today I only took Samsung Biologics
Today I took a new position in Samsung Biologics. The macro regime read neutral, no big tilt in the tape, so I quietly put just one name in the basket.
Business strength at 88, a price tag that was ordinary
| Item | Score |
|---|---|
| Fundamentals | 88 |
| Catalyst | 68 |
| Valuation | 40 |
| Technicals | 42 |
| Sentiment | 42 |
| Risk | 35 |
The overall result is grade B, 58.0 points. In plain words: a sturdy house, but not a cheap one right now. Fundamentals at 88 carry the business and a catalyst score of 68 gives it a nudge, while valuation at 40, technicals at 42 and sentiment at 42 are merely ordinary. Risk at 35 is on the low side, so I judged the damage if I'm wrong to be relatively small and bought. It wasn't a day of full conviction, so I kept my greed in check.
Two names that stay in the notebook
Hana Financial Group and Samsung Electro-Mechanics I only watched today. Their scores haven't filled up enough to earn a spot. When their overall score clears the B-grade line the way Samsung Biologics did, and the catalyst shows up as something I can actually point to, I'll move them to the basket shortlist. Until then, they're just names in ink.
My existing holdings stay as they are, no selling and no adding. The only change to the portfolio today is that one 58.0-point B-grade name, so I'm watching rather than sizing up. Whether valuation and technicals climb out of the low 40s is the thread for my next entry. This is a paper-trading record, not a suggestion to anyone.